Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers

Basit Öğe Kaydı
dc.contributor.authorFelip, Enriqueta
dc.contributor.authorSoria, Jean-Charles
dc.contributor.authorCobo, Manuel
dc.contributor.authorLu, Shun
dc.contributor.authorSyrigos, Kostas
dc.contributor.authorLee, Ki Hyeong
dc.contributor.authorGoker, Erdem
dc.contributor.authorGeorgoulias, Vassilis
dc.contributor.authorLi, Wei
dc.contributor.authorGuclu, Salih
dc.contributor.authorIsla, Dolores
dc.contributor.authorMin, Young Joo
dc.contributor.authorMorabito, Alessandro
dc.contributor.authorArdizzoni, Andrea
dc.contributor.authorGadgeel, Shirish
dc.contributor.authorDupuis, Nicholas
dc.contributor.authorGibson, Neil
dc.contributor.authorKraemer, Nicole
dc.contributor.authorBuehnemann, Claudia
dc.contributor.authorSolca, Flavio
dc.contributor.authorEhrnrooth, Eva
dc.contributor.authorGoss, Glenwood
dc.date.accessioned2019-10-27T11:19:31Z
dc.date.available2019-10-27T11:19:31Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.identifier.endpageS1187en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue1en_US
dc.identifier.startpageS1186en_US
dc.identifier.urihttps://hdl.handle.net/11454/32780
dc.identifier.volume12en_US
dc.identifier.wosWOS:000413055802480en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSquamous cell carcinoma of the lungen_US
dc.subjectNSCLCen_US
dc.subjectafatiniben_US
dc.titleSecond-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkersen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu